Twist Bioscience Stock Rallies As Guidance And Targets Jump

Twist Bioscience Corporation stocks have been trading up by 22.3 percent after strong synthetic DNA demand and bullish analyst upgrades.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For TWST Traders

Q3 revenue hit $118.4M, topping expectations around $114.5M and rising 23%+ year over year, even though the EPS loss widened to ($0.56).
Management lifted Q4 revenue guidance to $123M–$124M, well above prior consensus near $117.4M, and is targeting adjusted EBITDA breakeven.
Full-year FY26 revenue guidance moved up to $456M–$457M, above Street estimates in the mid-$440M range, with gross margin now expected above 52%.
TD Cowen, Piper Sandler, and Baird all raised TWST price targets to $115 with bullish ratings, citing AI-enabled drug discovery demand and a clearer path toward profitability.
A $300M upsized equity offering at $96 per share gives Twist Bioscience fresh capital for R&D, manufacturing expansion, and product development, though it adds dilution.

Live Update At 16:46:36 EDT: On Wednesday, August 19, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 22.3%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TWST has been trading like a classic high-growth story stock. The company just delivered Q3 revenue of $118.4M, beating estimates around $114.5M and growing more than 23% year over year. That top-line beat shows demand for Twist Bioscience’s synthetic DNA and tools remains strong. The flip side: TWST is still losing money, with EPS at ($0.56), wider than last year’s ($0.33).

On the chart, the story is momentum. In late July, TWST closed near $85–$92. After earnings and guidance, the stock ripped, with recent closes jumping from about $101 on 2026/08/03 to $142.39 on 2026/08/19. That is a huge trend move in a short window. Intraday, the 5‑minute data show steady higher lows through the afternoon, a sign dip-buyers are in control.

More Breaking News

Under the hood, Twist Bioscience posts a rich 77.9% gross margin but deeply negative operating margins and returns on equity. The balance sheet carries modest leverage and a current ratio of 2.7, so liquidity looks solid, especially after the new raise. For traders, TWST is a high-valuation, high-volatility name where sentiment and guidance matter as much as backward-looking earnings.

Why Traders Are Watching TWST Momentum

TWST is back on many momentum screens because the company is finally pairing big growth with a clearer path toward breakeven. Twist Bioscience raised fiscal Q4 revenue guidance to $123M–$124M, far above the $117.4M range the Street expected. Management also says Q4 should reach adjusted EBITDA breakeven. For a name that has run heavy losses for years, that line in the sand matters. It changes the narrative from “cash burner” to “approaching self-funding.”

At the same time, Twist Bioscience pushed FY26 revenue guidance up to $456M–$457M, above prior $442M–$447M and above consensus near $444.7M. The company now targets gross margin above 52%, building on that already strong 77.9% gross margin profile. TWST is telling the market it sees a bigger, more profitable business just ahead.

Wall Street is leaning into that story. TD Cowen bumped its TWST price target from $89 to $115 and kept a Buy rating, highlighting another year of triple-digit AI-enabled drug discovery order growth expected in FY27. Piper Sandler matched the $115 target and reiterated Overweight, arguing Twist Bioscience is building a higher long-term revenue base and is closing in on a cash-generative model. Baird also lifted its TWST target to $115 with an Outperform stance, reinforcing the bullish cluster.

There are offsets. TWST posted a larger-than-expected Q3 loss and swung from a profit a year earlier, and the stock briefly traded down about 6.3% pre-market as traders digested the numbers. On top of that, Twist Bioscience priced an upsized $300M secondary offering of 3.125M shares at $96, with a 30‑day option for 468,750 more. That adds dilution and can create a supply overhang near the $96 level. But it also strengthens the balance sheet for R&D and manufacturing expansion, which supports the growth story many TWST traders are chasing.

Conclusion

For active traders, TWST now sits in that tricky but exciting zone where fundamentals and momentum are finally pointing in the same direction. Twist Bioscience has revenue growth above 20%, raised Q4 and FY26 guidance, and is aiming for adjusted EBITDA breakeven in the near term. The AI-enabled drug discovery angle gives TWST a powerful narrative tailwind, and multiple firms — TD Cowen, Piper Sandler, and Baird — have converged on a $115 price target with bullish ratings.

At the same time, this is not a “set it and forget it” story. TWST still carries negative margins, high price‑to‑sales, and huge sensitivity to guidance changes. The $300M equity raise at $96 signals both confidence and the need for capital, and that level may act as a reference point for future trading support or resistance. The recent parabolic move from the $80s to the $140s adds another layer of volatility risk.

This content is for educational and research purposes only, but the trading lesson is clear. As Tim Sykes likes to say, “Patterns repeat because human emotions never change — your job is to recognize the pattern and manage your risk.” And as Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.”. With TWST, the pattern right now is strong growth, aggressive guidance, bullish analysts, fresh capital — and a stock pricing in a lot of hope. Traders studying Twist Bioscience should stay disciplined, watch the key levels, and let the chart confirm the story.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!